Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-overexpressed nutrient transporters represent a broad class of membrane-bound proteins, primarily within the Solute Carrier (SLC) superfamily, that are significantly upregulated in various malignancies to support the high metabolic demands of rapidly dividing cells [Nature Reviews Cancer](https://www.nature.com/articles/nrc3822). These transporters, including the glucose transporter GLUT1 (SLC2A1), amino acid transporters like LAT1 (SLC7A5) and ASCT2 (SLC1A5), and monocarboxylate transporters such as MCT1 (SLC16A1), facilitate the increased uptake of essential fuels and the removal of metabolic waste products [Frontiers in Pharmacology](https://www.frontiersin.org/articles/10.3389/fphar.2020.00586/full). This upregulation is a hallmark of the metabolic reprogramming known as the Warburg effect, which allows cancer cells to thrive in nutrient-deprived or hypoxic microenvironments [PubMed](https://pubmed.ncbi.nlm.nih.gov/23603611/). By selectively inhibiting these transporters, therapeutic strategies aim to disrupt the supply of building blocks and energy, effectively starving the tumor while potentially sparing normal tissues that express these proteins at lower levels [Clinical Cancer Research](https://clincancerres.aacrjournals.org/content/27/11/3016). Current drug development efforts focus on small-molecule inhibitors like JPH203 and AZD3965, which target specific transporters to induce metabolic catastrophe and enhance the efficacy of other chemotherapeutic agents [Journal of Clinical Oncology](https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3565).
Competitive or non-competitive inhibition of substrate binding sites on the transporter protein, preventing the translocation of nutrients (glucose, amino acids, or lactate) across the plasma membrane to induce metabolic stress and apoptosis [Nature Reviews Cancer](https://www.nature.com/articles/nrc3822).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-overexpressed nutrient transporters.